AGTC to Participate in the Stifel 2021 Virtual Healthcare Conference

Rhea-AI Summary

Applied Genetic Technologies Corporation (Nasdaq: AGTC) will have its President and CEO, Sue Washer, participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on November 17, 2021, at 10:40 a.m. ET. This event will focus on the company's advancements in gene therapies for rare inherited retinal diseases. An audio webcast of the presentation will be available here, with a replay accessible on AGTC’s website afterward.

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced that Sue Washer, President and Chief Executive Officer of AGTC, will be participating in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on November 17, 2021 at 10:40 a.m. ET.

An audio webcast of the presentation can be accessed by visiting http://ir.agtc.com/events-and-presentations. A replay will be available on the Company's website following the event.

About AGTC
AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies with the potential to address real patient needs. AGTC’s most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with an inherited retinal disease. AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 and ACHM CNGA3). Its preclinical programs build on the Company’s industry leading AAV manufacturing technology and scientific expertise. AGTC is also advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders, including entering into strategic partnerships with companies including Otonomy, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, and Bionic Sight, LLC, an innovator in the emerging field of optogenetics and retinal coding.

IR Contact: 
David Carey (IR)
Lazar FINN Partners
T: (212) 867-1768
david.carey@finnpartners.com

Corporate Contact:
Jonathan Lieber
Chief Financial Officer
Applied Genetic Technologies Corporation
T: (617) 843-5778  
jlieber@agtc.com

FAQ

When is AGTC's presentation at the Stifel 2021 Virtual Healthcare Conference?

AGTC's presentation is scheduled for November 17, 2021, at 10:40 a.m. ET.

Who will represent AGTC at the Stifel conference?

Sue Washer, the President and CEO of AGTC, will represent the company.

How can I listen to AGTC's presentation at the conference?

An audio webcast of AGTC's presentation can be accessed here.

What is the focus of AGTC's clinical programs?

AGTC's clinical programs focus on gene therapies for rare inherited retinal diseases.

What type of company is AGTC?

AGTC is a biotechnology company focusing on adeno-associated virus-based gene therapies.